WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Trial sites reduced: 71 → 59 locations
    • Enrollment target: estimated 164 to confirmed 168
    • Eligibility criteria expanded, about 32 words
  2. Study sites: 69 to 71v13
  3. Eligibility criteria expanded, about 126 words
    • Secondary endpoints revised (9)
    • Study description expanded, about 1 word
    v12
  4. Trial sites expanded: 65 → 69 locationsv11
  5. Trial sites expanded: 44 → 65 locationsv10
Show 8 earlier versionsHide 8 earlier versions
  1. Study sites: 32 to 44v9
  2. Study sites: 23 to 32v8
  3. Study sites: 17 to 23v7
  4. Study sites: 8 to 17v6
  5. Study sites: 4 to 8v5
  6. Study sites: 2 to 4v4
  7. Start date changed from estimate of May 2025 to May 5, 2025
    • Study sites revised (2)
    v3
  8. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
Trial Details
NCT Number NCT06967805
Lead Sponsor Mediar Therapeutics
Conditions
(from sponsor)		 Idiopathic Pulmonary Fibrosis
Related terms Fibrosis, Idiopathic Pulmonary Fibrosis
Enrollment 168 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov